Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 1681)

SUPPLEMENTAL ANNOUNCEMENT

IN RELATION TO THE ANNUAL REPORT

FOR THE YEAR ENDED 31 DECEMBER 2019

Reference is made to the annual report of Consun Pharmaceutical Group Limited (the "Company" ) for the year ended 31 December 2019 (the "Annual Report" ). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Annual Report.

In addition to the information provided in the paragraph headed "Share Option Scheme" in the Report of Directors and note 22(a) to the consolidated financial statements in the Annual Report, the Board would like to provide the following further information in relation to the share options for the year ended 31 December 2019:

Movements on the share options for the year ended 31 December 2019

Outstanding

Outstanding

as at

Granted

Exercised

Cancelled

Lapsed

as at

Tranche

1 January

during

during

during

during

31 December

Number

2019

the year

the year

the year

the year

2019

' 000

' 000

' 000

' 000

' 000

' 000

Directors

Mr. AN Yubao (1)

2014 T3 (2)

3,000

-

-

-

-

3,000

2014 T4 (2)

3,000

-

-

-

-

3,000

2016 T7 (2)

1,200

-

-

-

-

1,200

2016 T8 (2)

1,200

-

-

-

-

1,200

2016 T9 (2)

1,600

-

-

-

-

1,600

2019 T4 (3)

-

2,625

-

-

-

2,625

2019 T5 (3)

-

2,625

-

-

-

2,625

2019 T6 (3)

-

3,500

-

-

-

3,500

Sub-total

10,000

8,750

0

0

0

18,750

1

Outstanding

Outstanding

as at

Granted

Exercised

Cancelled

Lapsed

as at

Tranche

1 January

during

during

during

during

31 December

Number

2019

the year

the year

the year

the year

2019

' 000

' 000

' 000

' 000

' 000

' 000

Ms. LI Qian (1)

2014 T3 (2)

3,000

-

-

-

-

3,000

2014 T4 (2)

3,000

-

-

-

-

3,000

2016 T7 (2)

1,200

-

-

-

-

1,200

2016 T8 (2)

1,200

-

-

-

-

1,200

2016 T9 (2)

1,600

-

-

-

-

1,600

2019 T4 (3)

-

2,625

-

-

-

2,625

2019 T5 (3)

-

2,625

-

-

-

2,625

2019 T6 (3)

-

3,500

-

-

-

3,500

Sub-total

10,000

8,750

0

0

0

18,750

Professor ZHU Quan

2014 T1 (2)

720

-

-

-

-

720

2014 T2 (2)

480

-

-

-

-

480

2016 T4 (2)

600

-

-

-

-

600

2016 T5 (2)

358

-

-

-

-

358

2016 T6 (2)

800

-

-

-

(470)

330

2019 T1 (3)

-

240

-

-

-

240

2019 T2 (3)

-

240

-

-

-

240

2019 T3 (3)

-

320

-

-

-

320

Sub-total

2,958

800

0

0

(470)

3,288

Mr. TANG Ning

2014 T1 (2)

230

-

-

-

-

230

2014 T2 (2)

119

-

-

-

-

119

2016 T1 (2)

287

-

-

-

-

287

2016 T2 (2)

270

-

-

-

-

270

2016 T3 (2)

600

-

-

-

(216)

384

2019 T1 (3)

-

390

-

-

-

390

2019 T2 (3)

-

390

-

-

-

390

2019 T3 (3)

-

520

-

-

-

520

Sub-total

1,506

1,300

0

0

(216)

2,590

2

Outstanding

Outstanding

as at

Granted

Exercised

Cancelled

Lapsed

as at

Tranche

1 January

during

during

during

during

31 December

Number

2019

the year

the year

the year

the year

2019

' 000

' 000

' 000

' 000

' 000

' 000

Employees

In aggregate

2014 T1 (2)

3,266

-

-

-

-

3,266

2014 T2 (2)

3,266

-

-

-

-

3,266

2016 T1 (2)

7,190

-

(208)

-

(1,014)

5,968

2016 T2 (2)

7,190

-

(208)

-

(1,014)

5,968

2016 T3 (2)

9,587

-

(277)

-

(1,352)

7,958

2019 T1 (3)

-

13,020

-

-

(1,116)

11,904

2019 T2 (3)

-

13,020

-

-

(1,116)

11,904

2019 T3 (3)

-

17,360

-

-

(1,488)

15,872

Sub-total

30,499

43,400

(693)

0

(7,100)

66,106

Total

54,963

63,000

(693)

0

(7,786)

109,484

Notes:

  1. a substantial shareholder of the Company
  2. Share options granted before 1 January 2019:

Date of Grant

as per

Tranche

Board' s

Exercise

Number

approval

Vesting Period

Exercise Period

Price

from

to

from

to

DD/MM/YYYY

DD/MM/YYYY

DD/MM/YYYY

DD/MM/YYYY

DD/MM/YYYY

HKD

2014 T1

24/03/2014

24/03/2014

23/03/2015

24/03/2015

23/03/2024

6.64

2014 T2

24/03/2014

24/03/2014

23/03/2016

24/03/2016

23/03/2024

6.64

2014 T3

24/03/2014

28/05/2014*

23/03/2015

24/03/2015

23/03/2024

6.64

2014 T4

24/03/2014

28/05/2014*

23/03/2016

24/03/2016

23/03/2024

6.64

2016 T1

01/04/2016

01/04/2016

31/03/2017

01/04/2017

31/03/2026

4.01

2016 T2

01/04/2016

01/04/2016

31/03/2018

01/04/2018

31/03/2026

4.01

2016 T3

01/04/2016

01/04/2016

31/03/2019

01/04/2019

31/03/2026

4.01

2016 T4

01/04/2016

01/04/2016

31/03/2017

01/04/2017

31/03/2026

4.01

2016 T5

01/04/2016

01/04/2016

31/03/2018

01/04/2018

31/03/2026

4.01

2016 T6

01/04/2016

01/04/2016

31/03/2019

01/04/2019

31/03/2026

4.01

2016 T7

01/04/2016

27/05/2016*

31/03/2017

01/04/2017

31/03/2026

4.01

2016 T8

01/04/2016

27/05/2016*

31/03/2018

01/04/2018

31/03/2026

4.01

2016 T9

01/04/2016

27/05/2016*

31/03/2019

01/04/2019

31/03/2026

4.01

  • the date on which the relevant shareholders' approval was granted

3

3. Share options granted during the year ended 31 December 2019:

Date of Grant

Tranche

as per Board' s

Exercise

Option

Number

approval

Vesting Period

Exercise Period

Price

Value

from

to

from

to

DD/MM/YYYY

DD/MM/YYYY

DD/MM/YYYY

DD/MM/YYYY

DD/MM/YYYY

HKD

HKD

2019 T1

02/01/2019

02/01/2019

31/03/2020

01/04/2020

01/01/2029

4.476

1.4434

2019 T2

02/01/2019

02/01/2019

31/03/2021

01/04/2021

01/01/2029

4.476

1.4900

2019 T3

02/01/2019

02/01/2019

31/03/2022

01/04/2022

01/01/2029

4.476

1.5317

2019 T4

02/01/2019

31/05/2019*

31/03/2020

01/04/2020

01/01/2029

4.476

1.9825

2019 T5

02/01/2019

31/05/2019*

31/03/2021

01/04/2021

01/01/2029

4.476

2.0625

2019 T6

02/01/2019

31/05/2019*

31/03/2022

01/04/2022

01/01/2029

4.476

2.1216

  • the date on which the relevant shareholders' approval was granted

During the year ended 31 December 2019, the Board approved the grant of 63,000,000 share options to certain Directors and eligible employees of the Group on 2 January 2019 with an exercise price of HKD4.476 and the closing price of the Company' s shares immediately before the date of such grant was HKD4.55.

During the year ended 31 December 2019, all of the 693,000 exercised share options were exercised by the Group' s employees at the exercise price of HKD4.01 and the weighted average closing price of the Company' s shares immediately before the dates on which such share options were exercised was HKD4.8196.

The share option value is measured based on a binomial tree model and the total value of share options granted during the year ended 31 December 2019 is as follows:

Total value of

Share options granted to:

share options

HKD' 000

Directors

Mr. AN Yubao *

18,044

Ms. LI Qian *

18,044

Professor ZHU Quan

1,194

Mr. TANG Ning

1,940

Employees

In aggregate

64,783

Total

104,005

  • a substantial shareholder of the Company

The total value of share options granted is charged to profit or loss as part of staff costs over the vesting period taking into account the probability that the share options will vest.

4

In addition, the remaining life of the Share Option Scheme, which will expire on 1 December 2023, is approximately 3 years 8 months from the date of the Annual Report (i.e. 23 March 2020) and there is no minimum period for which a share option must be held before it can be exercised pursuant to the terms of the Share Option Scheme.

The above additional information does not affect other information contained in the Annual Report. Save as disclosed in this announcement, all other information in the Annual Report remains unchanged.

By order of the Board

Consun Pharmaceutical Group Limited

AN Yubao

Chairman of the Board

Hong Kong, 26 August 2020

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.

5

Attachments

  • Original document
  • Permalink

Disclaimer

Consun Pharmaceutical Group Ltd. published this content on 26 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 August 2020 11:11:04 UTC